NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas
Open Access
- 14 June 2019
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 8 (9) , 4330-4337
Abstract
The tumor suppressor gene neurofibromin 1 (NF1) is a major regulator of the RAS‐MAPK pathway. NF1 mutations occur in lung cancer but were not extensively explored. We hypothesized that NF1‐mutated tumors could define a specific population with a distinct clinical and molecular profile. We performed NF1 sequencing using next generation sequencing (NGS) in 154 lung adenocarcinoma surgical specimens with known KRAS, EGFR, TP53, BRAF, HER2, and PIK3CA status, to evaluate the molecular and clinical specificities of NF1‐mutated lung cancers. Clinical data were retrospectively collected, and their associations with molecular profiles assessed. In this series, 24 tumors were NF1 mutated (17.5%) and 11 were NF1 deleted (8%). There was no mutation hotspot. NF1 mutations were rarely associated with other RAS‐MAPK pathway mutations. Most of patients with NF1 alterations were males (74.3%) and smokers (74.3%). Overall survival and disease‐free survival were statistically better in patients with NF1 alterations (N = 34) than in patients with KRAS mutations (N = 30) in univariate analysis. Our results confirm that NF1 is frequently mutated and represents a distinct molecular and clinical subtype of lung adenocarcinoma.Keywords
Funding Information
- Cancer Research for Personalized Medicine program
This publication has 41 references indexed in Scilit:
- A method and server for predicting damaging missense mutationsNature Methods, 2010
- Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithmNature Protocols, 2009
- Human Splicing Finder: an online bioinformatics tool to predict splicing signalsNucleic Acids Research, 2009
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- TORC1 Is Essential for NF1-Associated MalignanciesCurrent Biology, 2008
- Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar DifferentiationAmerican Journal of Surgical Pathology, 2006
- Ras, PI(3)K and mTOR signalling controls tumour cell growthNature, 2006
- The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysisBritish Journal of Cancer, 2004
- Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferationOncogene, 1999